重组人血清白蛋白的研究进展

Progresses in Recombinant Human Serum Albumin

人血清白蛋白(Human serum albumin,HSA)是现代医学中一种重要的临床生物制品,主要用于维持血浆胶体渗透压及作为血浆容量扩充剂,广泛应用于出血性休克、烧伤、癌症、白细胞增多症、白蛋白过少症等。HSA主要靠收集人的血液分级过滤获得,有可能被病毒、致病蛋白粒子等污染。目前人们利用生物工程技术表达重组人血清白蛋白(Recom binant HSA,rHSA),其结构和功能与血浆来源的血清白蛋白(Plasma derived HSA,pdHSA)相似。预临床和临床试验已证明rHSA可安全地应用于多种疾病治疗。

Human serum albumin （HSA） is an important biological product in clinical pharmacy practice at present. Its main clinical use is in maintaining colloid osmotic pressure and increasing circulating plasma volume so as to cure hemorrhagic shock, burn, cancer, hypercytosis, hypoalbuminosis, etc. HSA is isolated by fractionating human plasma, which entails possible contamination by viruses or prions. Recombinant human serum albumin （rHSA） has been successfully produced by biological engineering. The structural and functional properties of rHSA are similar to those of plasma derived human serum albumin （pdHSA）. Preclinical and clinical trials have confirmed the safety and efficacy of using this rHSA preparation in the treatment of certain diseases.